Abstract
Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α / ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand , and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.
Keywords: hepatitis c virus, interferon-a, ribavirin, b iymphocytes, endotoxins
Current Pharmaceutical Design
Title: The Immune Responsiveness in Hepatitis C Virus Infected Patients: Effects of Interferon-Alfa / Ribavirin Combined Treatment on the Lymphocyte Response with Special Reference to B Cells
Volume: 10 Issue: 17
Author(s): L. Amati, R. Cozzolongo, O. G. Manghisi, R. Cuppone, N. M. Pellegrino, D. Caccavo and E. Jirillo
Affiliation:
Keywords: hepatitis c virus, interferon-a, ribavirin, b iymphocytes, endotoxins
Abstract: Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α / ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand , and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.
Export Options
About this article
Cite this article as:
Amati L., Cozzolongo R., Manghisi G. O., Cuppone R., Pellegrino M. N., Caccavo D. and Jirillo E., The Immune Responsiveness in Hepatitis C Virus Infected Patients: Effects of Interferon-Alfa / Ribavirin Combined Treatment on the Lymphocyte Response with Special Reference to B Cells, Current Pharmaceutical Design 2004; 10 (17) . https://dx.doi.org/10.2174/1381612043384231
DOI https://dx.doi.org/10.2174/1381612043384231 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunotherapy in Gastric Carcinoma: Current Status and Future Perspectives
Clinical Cancer Drugs Cordycepin Suppresses Integrin/FAK Signaling and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques
Current Topics in Medicinal Chemistry Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging From Bone Marrow Transplantation to Cellular Therapies: Possible Therapeutic Strategies in Managing Autoimmune Disorders
Current Pharmaceutical Design Self-Assembled Micelles of Amphiphilic PEGylated Drugs for Cancer Treatment
Current Drug Targets Recent Patents Concerning Diagnostic and Therapeutic Applications of Aberrantly Methylated Sequences in Pancreatic Cancer
Recent Patents on DNA & Gene Sequences Statins and epilepsy: preclinical studies, clinical trials and statin-anticonvulsant drug interactions
Current Drug Targets Dynamics of CD86 Expression on Allergic Inflammation - New Insights
Recent Patents on Inflammation & Allergy Drug Discovery Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy Dietary Phenolic Acids and Flavonoids as Potential Anti-Cancer Agents: Current State of the Art and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Plant Glycosides and Aglycones Displaying Antiproliferative and Antitumour Activities – A Review
Current Bioactive Compounds Comprehensive Profiling of Protein Ubiquitination for Drug Discovery
Current Pharmaceutical Design Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Synthesis of 2-(Bis (2-Chloroethyl)Amino)-N-(5-Substitutedphenyl)- 1,3,4- Thiadiazol-2-Yl)Acetohydrazide And Evaluation of Anticancer Activity
Current Bioactive Compounds LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Potentiating Effect of Ethnomedicinal Plants Against Proliferation on Different Cancer Cell Lines
Current Drug Metabolism Discovery and Design of Peptides as MMP9 Inhibitors through Structure-Based Molecular Docking for Targeted Mantle Cell Lymphoma Therapy
Anti-Cancer Agents in Medicinal Chemistry Alpha-Helical Cationic Anticancer Peptides: A Promising Candidate for Novel Anticancer Drugs
Mini-Reviews in Medicinal Chemistry